Phase I Study of Bendamustine in Combination with Lenalidomide (CC-501 3) and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma

Trial Profile

Phase I Study of Bendamustine in Combination with Lenalidomide (CC-501 3) and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Bendamustine (Primary) ; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 27 Oct 2014 Planned End Date changed from 1 Jun 2014 to 1 Mar 2015, according to the the ClinicalTrials.gov record.
    • 15 Jan 2014 Planned End Date changed from 1 Jan 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top